Keryx Biopharmaceuticals Appoints VP, Marketing And Strategy
Keryx Biopharmaceuticals Inc., a biopharma specialising in the treatment of renal disease, has appointed Douglas Jermasek vice president of marketing and strategy. Jermasek has more than 20 years of biopharma strategic marketing experience, having held senior leadership roles at several companies, including Deltanoid Pharmaceuticals, Intercept Pharmaceuticals and Genzyme/Sanofi’s global renal business, where he reached the position of senior vice president and general manager.
You may also be interested in...
The UK backs the world's first COVID-19 human challenge studies to accelerate research – though the first results will not be ready until mid-2021.
New chief business officer named at Ovoca Bio, and a new chairman at Opthea Ltd.
Plus Sanofi and Translate Bio release preclinical data from their COVID-19 vaccine candidate, another entrant to the now crowded mRNA vaccine field.